April 12, 2021
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer BookmarkGeorge Lundberg, MD
An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.
December 2, 2019
Does the Artery-first Approach Improve the Rate of R0 Resection in Pancreatoduodenectomy?: A Multicenter, Randomized, Controlled Trial BookmarkGeorge Lundberg, MD
Research paper from Annals of Surgery curated by Editor in Chief George Lundberg, MD, who notes:
This clinical trial found no difference in tumor-free margins from standard versus artery-first surgical techniques for the resection of pancreatic head adenocarcinoma via pancreatoduodenectomy.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.